The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review
Open accessAbstract
Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the treatment of polymicrobial infections caused by multidrug-resistant Gram-positive and Gram-negative pathogens. Tigecycline evades the main tetracycline resistance genetic mechanisms, such as tetracycline-specific efflux pump acquisition and ribosomal protection, via the addition of a glycyclamide moiety to the 9-position of minocycline. The use of the parenteral form of tigecycline is approved for complicated skin and skin structure infections (excluding diabetes foot infection), complicated intra-abdominal infections, and community-acquired bacterial pneumonia in adults. New evidence also suggests the effectiveness of tigecycline for the treatment of severe Clostridioides difficile infections. Tigecycline showed in vitro susceptibility to Coxiella spp., Rickettsia spp., and multidrug-resistant Neisseria gonnorrhoeae strains which indicate the possible use of tigecycline in the treatment of infections caused by these pathogens. Except for intrinsic, or often reported resistance in some Gram-negatives, tigecycline is effective against a wide range of multidrug-resistant nosocomial pathogens. Herein, we summarize the currently available data on tigecycline pharmacokinetics and pharmacodynamics, its mechanism of action, the epidemiology of tigecycline resistance, and its clinical effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibiotic resistance crisis: part 1: causes and threats.
Ventola, C. L. (2015) · PubMed · Cited by 4,516
Performance standards for antimicrobial susceptibility testing
Weinstein, M. P., & Clinical (2019) · Clinical and Laboratory Standards Institute eBooks · Cited by 4,341
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1229963 · Cited by 2,541
The American Journal of Tropical Medicine and Hygiene
Gifpen, H. K. (1952) · American Journal of Clinical Pathology · doi:10.1093/ajcp/22.10.992b · Cited by 1,891
Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa
Li, X. Z., Nikaido, H., & Poole, K. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1948 · Cited by 643
Ko¨hler, T., Michéa‐Hamzehpour, M., Henze, U., Gotoh, N., Kocjancic Curty, L., & Pechère, J. (1997) · Molecular Microbiology · doi:10.1046/j.1365-2958.1997.2281594.x · Cited by 549
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon
Alekshun, M. N., & Levy, S. B. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2067 · Cited by 470
Poole, K., Gotoh, N., Tsujimoto, H., Zhao, Q., Wada, A., Yamasaki, T., Neshat, S., Yamagishi, J., Li, X., & Nishino, T. (1996) · Molecular Microbiology · doi:10.1046/j.1365-2958.1996.281397.x · Cited by 443
Cited by
Klebsiella pneumoniae carbapenemase variants: the new threat to global public health
Ding, L., Shen, S., Chen, J., Tian, Z., Shi, Q., Han, R., Guo, Y., & Hu, F. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-23 · Cited by 222
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens
Saxena, D., Maitra, R., Bormon, R., Czekanska, M., Meiers, J., Titz, A., Verma, S., & Chopra, S. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00016-1 · Cited by 217
Metadata
- Authors
- Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., & Maleki, F.
- Venue
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2021-01-05
- Volume
- 41
- Issue
- 7
- Pages
- 1003-1022
- ISSN
- 0934-9723 (ISSN-L)
- 1435-4373
- OpenAlex
- W3119231599
- Cited by
- 332
- References
- 144
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. https://app.cochat.ai/papers/10.1007/s10096-020-04121-1
- The paper
- Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., & Maleki, F. (2022). Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-020-04121-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.